Pelvic Angiography in Non-Responders to Phosphodiesterase-5 Inhibitors (PANPI)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

10 participants

Study Classification

OBSERVATIONAL

Study Start Date

2005-08-31

Study Completion Date

2008-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The specific aim of this pilot study is to describe the angiographic prevalence and pattern of internal pudendal artery (and associated inflow vessel) atherosclerosis in patients with erectile dysfunction who are non-responsive to PDE-5 inhibitors (i.e., Viagra) who are referred for clinically-indicated cardiac catheterization.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The specific aim of this study is to determine if the deep penile arteries can be seen angiographically from the iliac arteries to delineate penile vasculature. Significant obstructive atherosclerotic disease of the deep penile arteries may be present in impotent males. The etiology of erectile dysfunction is multifactorial and may involve vascular disease, endocrine disorders, neurologic disease, prescription medications, psychological issues and/or trauma in any given patient. Vascular disease in patients with erectile dysfunction may be due to trauma, congenital anomalies, or atherosclerosis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Erectile Dysfunction

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

ED Erectile Dysfunction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male patients
* at least 50 years
* erectile dysfunction
* dissatisfaction with their use of a phosphodiesterase-5 inhibitor
* coronary artery disease (or at risk for coronary artery disease)
* undergoing diagnostic cardiac catheterization or patients with peripheral vascular disease undergoing peripheral arteriography

Exclusion Criteria

* Patients who respond favorably to phosphodiesterase-5 inhibitors
* known non-vascular etiologies of their erectile dysfunction
* probable neurogenic erectile dysfunction due to radiation injury, surgery, or transurethral resection of the prostate
* calculated GFR \< 60 ml/min/1.73 m2 will also be excluded
* disease that necessitates complex percutaneous intervention will be excluded per the investigators discretion

Minimum Eligible Age

50 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jason Rogers, MD

Role: PRINCIPAL_INVESTIGATOR

University of California, Davis

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

200513528

Identifier Type: -

Identifier Source: org_study_id